OBJECTIVE: To determine if there are significant differences in biochemical characteristics, biopsy variables, histopathological data, and rates of prostate-specific antigen (PSA) recurrence between African-American (AA) and white American (WA) men undergoing radical prostatectomy (RP), as AA men are twice as likely to die from prostate cancer than their white counterparts. PATIENTS AND METHODS: We established a cohort of 1058 patients (402 AA, 646 WA) who had RP and were followed for PSA recurrence. Age, race, serum PSA, biopsy Gleason score, clinical stage, pathological stage, and PSA recurrence data were available for the cohort. The chi-square test of proportions and t-tests were used to assess basic associations with race, and log-rank tests and Cox regression models for time to PSA recurrence. Forward stepwise variable selection was used to assess the effect on the risk of PSA recurrence for race, adjusted by the other variables added one at a time. RESULTS: The AA men had higher baseline PSA levels, more high-grade prostatic intraepithelial neoplasia (HGPIN) in the biopsy, and more HGPIN in the pathology specimen than WA men. The AA men also had a shorter mean (sd) PSA doubling time before RP, at 4.2 (4.7) vs 5.2 (5.9) years. However, race was not an independent predictor of PSA recurrence (P = 0.225). Important predictors for PSA recurrence in a multivariable model were biopsy HGPIN (P < 0.014), unilateral vs bilateral cancer (P < 0.006), pathology Gleason score and positive margin status (both P < 0.001). CONCLUSIONS: This study indicates that while there are racial differences in baseline serum PSA and incidence of HGPIN, race is not an independent risk factor for PSA recurrence. Rather, other variables such as pathology Gleason score, bilateral cancers, HGPIN and margin positivity are independently associated with PSA recurrence. The PSA doubling time after recurrence may also be important, leading to the increased mortality of AA men with prostate cancer.
OBJECTIVE: To determine if there are significant differences in biochemical characteristics, biopsy variables, histopathological data, and rates of prostate-specific antigen (PSA) recurrence between African-American (AA) and white American (WA) men undergoing radical prostatectomy (RP), as AA men are twice as likely to die from prostate cancer than their white counterparts. PATIENTS AND METHODS: We established a cohort of 1058 patients (402 AA, 646 WA) who had RP and were followed for PSA recurrence. Age, race, serum PSA, biopsy Gleason score, clinical stage, pathological stage, and PSA recurrence data were available for the cohort. The chi-square test of proportions and t-tests were used to assess basic associations with race, and log-rank tests and Cox regression models for time to PSA recurrence. Forward stepwise variable selection was used to assess the effect on the risk of PSA recurrence for race, adjusted by the other variables added one at a time. RESULTS: The AA men had higher baseline PSA levels, more high-grade prostatic intraepithelial neoplasia (HGPIN) in the biopsy, and more HGPIN in the pathology specimen than WA men. The AA men also had a shorter mean (sd) PSA doubling time before RP, at 4.2 (4.7) vs 5.2 (5.9) years. However, race was not an independent predictor of PSA recurrence (P = 0.225). Important predictors for PSA recurrence in a multivariable model were biopsy HGPIN (P < 0.014), unilateral vs bilateral cancer (P < 0.006), pathology Gleason score and positive margin status (both P < 0.001). CONCLUSIONS: This study indicates that while there are racial differences in baseline serum PSA and incidence of HGPIN, race is not an independent risk factor for PSA recurrence. Rather, other variables such as pathology Gleason score, bilateral cancers, HGPIN and margin positivity are independently associated with PSA recurrence. The PSA doubling time after recurrence may also be important, leading to the increased mortality of AA men with prostate cancer.
Authors: B A Rybicki; O N Kryvenko; Y Wang; M Jankowski; S Trudeau; D A Chitale; N S Gupta; A Rundle; D Tang Journal: Prostate Cancer Prostatic Dis Date: 2015-12-01 Impact factor: 5.554
Authors: Oleksandr N Kryvenko; Yun Wang; Sudha Sadasivan; Nilesh S Gupta; Craig Rogers; Kevin Bobbitt; Dhananjay A Chitale; Andrew Rundle; Deliang Tang; Benjamin A Rybicki Journal: Prostate Date: 2019-05-02 Impact factor: 4.104
Authors: Margaret S Pichardo; Cheryl J Smith; Tiffany H Dorsey; Christopher A Loffredo; Stefan Ambs Journal: Cancer Epidemiol Biomarkers Prev Date: 2018-05-21 Impact factor: 4.254
Authors: Michael Koscuiszka; David Hatcher; Paul J Christos; Amy E Rose; Holly S Greenwald; Ya-lin Chiu; Samir S Taneja; Madhu Mazumdar; Peng Lee; Iman Osman Journal: Cancer Date: 2011-10-21 Impact factor: 6.860
Authors: Amy E Rose; Jaya M Satagopan; Carole Oddoux; Qin Zhou; Ruliang Xu; Adam B Olshen; Jessie Z Yu; Atreya Dash; Jerome Jean-Gilles; Victor Reuter; William L Gerald; Peng Lee; Iman Osman Journal: J Transl Med Date: 2010-07-22 Impact factor: 5.531
Authors: Deliang Tang; Jason J Liu; Cathryn H Bock; Christine Neslund-Dudas; Andrew Rundle; Adnan T Savera; James J Yang; Nora L Nock; Benjamin A Rybicki Journal: Int J Cancer Date: 2007-09-15 Impact factor: 7.396
Authors: David Schreiber; Justin Rineer; Jeffrey P Weiss; Joseph Safdieh; Joseph Weiner; Marvin Rotman; David Schwartz Journal: Radiat Oncol J Date: 2015-03-31